PriceTargets.com logo

Zynex - ZYXI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $10.25
  • Forecasted Upside: 246.87%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.96 As of 03/14/2025 12:48 PM ET
▲ +0.045 (1.55%)

This chart shows the closing price for ZYXI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$2.90Closing price on 03/13/25:
Get New Zynex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZYXI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYXI

Analyst Price Target is $10.25
▲ +246.87% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Zynex in the last 3 months. The average price target is $10.25, with a high forecast of $15.00 and a low forecast of $5.50. The average price target represents a 246.87% upside from the last price of $2.96.

This chart shows the closing price for ZYXI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/253/26$2.03$5.27$8.52$12$15Closing price on 03/13/25: $2.90High$15.00Average$10.25Low$5.50




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Zynex. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/19/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/11/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/13/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/12/2025HC WainwrightLower TargetBuy ➝ Buy$17.00 ➝ $15.00
3/12/2025Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$11.00 ➝ $5.50
3/12/2025LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
12/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
10/25/2024HC WainwrightBoost TargetBuy ➝ Buy$16.00 ➝ $17.00
10/8/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$12.00 ➝ $11.00
9/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
7/26/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$15.00 ➝ $12.00
7/26/2024HC WainwrightLower TargetBuy ➝ Buy$21.00 ➝ $16.00
6/14/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$15.00 ➝ $15.00
5/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$21.00
3/1/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$13.00 ➝ $15.00
3/1/2024HC WainwrightBoost TargetBuy ➝ Buy$20.00 ➝ $21.00
10/16/2023Royal Bank of CanadaInitiated CoverageOutperform$13.00
4/12/2023HC WainwrightReiterated RatingBuy$20.00
3/28/2023LADENBURG THALM/SH SHBoost TargetBuy$27.00 ➝ $28.00
3/14/2023HC WainwrightLower TargetBuy$21.00 ➝ $20.00
1/6/2023Piper SandlerUpgradeNeutral ➝ Overweight$10.00 ➝ $18.00
10/28/2022B. RileyBoost Target$11.00 ➝ $12.50
10/28/2022HC WainwrightBoost TargetBuy$20.00 ➝ $21.00
10/28/2022Piper SandlerBoost TargetNeutral$7.00 ➝ $10.00
8/16/2022HC WainwrightReiterated RatingBuy$20.00
7/29/2022HC WainwrightReiterated RatingBuy
2/28/2022B. RileyLower TargetBuy$15.50 ➝ $10.00
2/25/2022HC WainwrightLower TargetBuy$22.00 ➝ $20.00
2/25/2022Piper SandlerLower Target$13.00 ➝ $7.00
11/2/2021Piper SandlerLower TargetNeutral$15.00 ➝ $13.00
10/14/2021HC WainwrightReiterated RatingBuy$22.00
7/30/2021HC WainwrightLower TargetBuy$25.00 ➝ $22.00
7/16/2021Northland SecuritiesReiterated RatingBuy$22.50
7/16/2021HC WainwrightReiterated RatingBuy$25.00
7/16/2021B. RileyUpgradeNeutral ➝ Buy$19.00 ➝ $19.50
3/15/2021Northland SecuritiesUpgradeMarket Perform ➝ Outperform
3/9/2021Northland SecuritiesUpgradeMarket Perform ➝ Outperform$22.50
2/26/2021B. RileyDowngradeBuy ➝ Neutral$19.00
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$28.00 ➝ $20.00
1/28/2021Northland SecuritiesDowngradeOutperform ➝ Market Perform$22.50
10/28/2020Northland SecuritiesReiterated RatingBuy$22.50
9/14/2020HC WainwrightUpgradeNeutral ➝ Buy
9/9/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$22.50
7/29/2020B. RileyUpgradeNeutral ➝ Buy$28.00
7/29/2020Northland SecuritiesReiterated RatingHold$22.50
7/29/2020HC WainwrightLower TargetNeutral$30.00 ➝ $25.00
7/20/2020Piper SandlerInitiated CoverageOverweight$30.00
7/13/2020B. RileyDowngradeBuy ➝ Neutral
7/10/2020HC WainwrightReiterated RatingNeutral$20.00 ➝ $30.00
6/16/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform$21.00
5/29/2020B. RileyBoost TargetBuy$18.50 ➝ $25.50
5/19/2020Northland SecuritiesReiterated RatingBuy$21.00
5/19/2020HC WainwrightDowngradeBuy ➝ Neutral$20.00
4/29/2020HC WainwrightReiterated RatingBuy$15.00 ➝ $20.00
4/8/2020HC WainwrightReiterated RatingBuy$15.00
4/1/2020Northland SecuritiesInitiated CoverageOutperform$15.00
3/30/2020B. RileyLower TargetBuy$20.50 ➝ $18.50
(Data available from 3/14/2020 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/15/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/15/2024
  • 8 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/14/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/14/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/13/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/12/2025
  • 6 very positive mentions
  • 24 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
3/14/2025

Current Sentiment

  • 6 very positive mentions
  • 24 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Zynex logo
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Read More

Today's Range

Now: $2.96
Low: $2.90
High: $3.13

50 Day Range

MA: $7.52
Low: $2.90
High: $8.36

52 Week Range

Now: $2.96
Low: $2.77
High: $13.19

Volume

277,165 shs

Average Volume

133,230 shs

Market Capitalization

$94.10 million

P/E Ratio

19.73

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Zynex?

The following sell-side analysts have issued stock ratings on Zynex in the last twelve months: HC Wainwright, LADENBURG THALM/SH SH, and Royal Bank of Canada.
View the latest analyst ratings for ZYXI.

What is the current price target for Zynex?

0 Wall Street analysts have set twelve-month price targets for Zynex in the last year. Their average twelve-month price target is $10.25, suggesting a possible upside of 246.9%. HC Wainwright has the highest price target set, predicting ZYXI will reach $15.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $5.50 for Zynex in the next year.
View the latest price targets for ZYXI.

What is the current consensus analyst rating for Zynex?

Zynex currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ZYXI, but not buy more shares or sell existing shares.
View the latest ratings for ZYXI.

What other companies compete with Zynex?

Other companies that are similar to Zynex include Embecta, CeriBell, AxoGen, Bioventus and Beta Bionics. Learn More about companies similar to Zynex.

How do I contact Zynex's investor relations team?

Zynex's physical mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company's listed phone number is (303) 703-4906 and its investor relations email address is info@zynex.com. The official website for Zynex is www.zynex.com. Learn More about contacing Zynex investor relations.